{"id":19051,"date":"2022-01-14T10:43:18","date_gmt":"2022-01-14T09:43:18","guid":{"rendered":"https:\/\/www.idisantiago.es\/grupo-de-investigacion\/c025-nanobiofar\/"},"modified":"2026-03-06T12:53:29","modified_gmt":"2026-03-06T11:53:29","slug":"c025-nanobiofar","status":"publish","type":"project","link":"https:\/\/www.idisantiago.es\/en\/grupo-de-investigacion\/c025-nanobiofar\/","title":{"rendered":"C025 – NANOBIOFAR"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||||false|false” da_disable_devices=”off|off|off” global_colors_info=”{}” da_is_popup=”off” da_exit_intent=”off” da_has_close=”on” da_alt_close=”off” da_dark_close=”off” da_not_modal=”on” da_is_singular=”off” da_with_loader=”off” da_has_shadow=”on”][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” custom_padding=”0px||||false|false” locked=”on” collapsed=”on” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\u00c1REA: ONCOLOG\u00cdA<\/a><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” width=”100%” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.idisantiago.es\/wp-content\/uploads\/2021\/11\/grupo_investigacion.jpg” title_text=”Corporate portrait of office workers and employees” disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” disabled=”on” global_colors_info=”{}”][\/et_pb_image][et_pb_toggle title=”Objectives and lines of research” disabled_on=”off|off|off” admin_label=”Objetivos y l\u00edneas de investigaci\u00f3n” _builder_version=”4.21.0″ _module_preset=”default” body_font=”|300|||||||” global_colors_info=”{}”]<\/p>\n

Objectives<\/h3>\n

Our scientific research concerns the use of nanotechnologies for the development of innovative drug\/antigen delivery systems. Our main objective is the design and development of new nanostructured materials intended for the transport of drugs and antigens across biological barriers and delivering them to the target tissue. Within this broad area, our main competence concerns the association of delicate molecules, including peptides, siRNA, antigens to these nanocarriers. Much of this research has been defined to have a special impact on the development of the nations of the world.<\/p>\n

Lines of research<\/h3>\n